Publications
182
Citations
12,067
Est. group size
—
Recurring co-author estimate
Active years
43
Publishing since 1983
Theodore F. Logan conducts clinical cancer research focused on treatments for melanoma (skin cancer) and kidney cancers such as renal cell carcinoma. Much of the work involves clinical trials of immunotherapies—treatments that harness the immune system, including cell-based therapies, checkpoint inhibitors, and combination drug regimens—as well as targeted therapies. Studies often report on safety and long-term outcomes for patients with advanced disease.
Publication activity has fluctuated year to year, with a pronounced spike in 2023 and an average of about seven publications per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- NyokAssist™ Percutaneous Ventricular Assist Device with Foldable Catheter Pump: Early Report from Clinical Trial
The Journal of Heart and Lung Transplantation · 2025
- Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study
Journal of Clinical Oncology · 2025
- NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Journal of the National Comprehensive Cancer Network · 2024
- SUPPLEMENTAL MATERIALS from Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
2023
- Data from Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
2023
- Data from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
2023
- Data from Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
2023
- Data from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
2023
- Supplementary Tables and Figures from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
2023
- Supplementary Figure 4a from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
2023
- Supplementary Figure 2 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
2023
- Supplementary Figure 1 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
2023
- Supplementary Figure 3 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
2023
- Supplementary Figure 4B from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
2023
- SUPPLEMENTAL MATERIALS from Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
2023
- Journal of Clinical Oncology×21
- Journal for ImmunoTherapy of Cancer×4
- Clinical Cancer Research×3
- The Lancet Oncology×2
- Cancer×2
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile